Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.
Journal Information
Full Title: J Antimicrob Chemother
Abbreviation: J Antimicrob Chemother
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Anti-Infective Agents
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Transparency declarations: The authors declare the following competing financial interest(s): Shionogi has applied for a patent on ensitrelvir. T.K., H.N., K.F., K.B., K.M., S.Y., Y.T., R.W., R.O., Y.K., K.I., S.K., A.Y., Y.H.K., M.T., Q.Z., Y.T., T.K., and T.S. are employees of Shionogi & Co., Ltd., and its subsidiary company."
"Funding This work was supported by internal funding from Shionogi & Co., Ltd."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025